
It’s conference week! This Thursday, the rare disease research community will come together at University College Dublin for a full day of research, lived experience, clinical trial updates, innovation and discussion.

Board Member - Irish Lung Fibrosis Association (@ILFA_Ireland) and European Pulmonary Fibrosis Federation (@EU_IPFF), Patient Co-Chair @ErnLung,

It’s conference week! This Thursday, the rare disease research community will come together at University College Dublin for a full day of research, lived experience, clinical trial updates, innovation and discussion.

@ILFA_Ireland calls on Government, HSE and relevant stakeholders to prioritise lung transplantation as a matter of urgency. This includes sustained investment in transplant services, ongoing donor awareness campaigns, & transparent reporting/accountability ilfa.ie/blog/organ-donor-awa…

Today is #WorldAsthmaDay! 💙 ELF provides free, reliable information about #Asthma in 9 languages to support people living with the condition around the world. Learn more: europeanlung.org/en/informat…

Huge congrats Sarah Forde for reaching the finals of #ENGAGE2026! Sarah presented "A Faulty Switch: How One Cell Trips the Lung Circuit" to a packed house. Well done to Sarah and her supervisors on their rare disease research.

Today is Alpha‑1 Awareness Day 💙 Learn more about alpha-1 antitrypsin deficiency (#AATD), a rare genetic lung condition and help raise awareness. Earlier understanding can lead to earlier diagnosis and improved support. 🔗: europeanlung.org/en/informat…

The next online ILFA Patient Information Day will take place on Tuesday, 31st March at 2pm. Please register via the link below. us02web.zoom.us/webinar/regi…

European Respiratory Journal: Fan-to-face therapy is a simple, feasible, low-cost, low-resource nonpharmacological approach to reduce exertional breathlessness during exercise training in adults with chronic lung disease bit.ly/4oMpcbX

RDCTN and @UCDMedicine were delighted to host the inaugural PH-ILD Forum in collaboration with @UnivParisSaclay and Royal Brompton Hospital/@imperialcollege. The meeting brought together global experts from 14 countries!

Great news for the patient community
Approved today: the first ever approved therapy for bronchiectasis in Europe Congratulations investigators, patients and Insmed Science changes lives European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union - Nov 18, 2025 investor.insmed.com/2025-11-…

🚨Free educational opportunity: apply now for the ERN-LUNG Academy 2026 We are calling on medical professionals across the EU to apply for the opportunity to develop their knowledge of rare respiratory diseases. Apply by 30 November, 2025 – learn more: bit.ly/3L6KjqY

The first patient-centered studio session at #ERSCongress! 💙 Co-chaired by patient representatives Helen Parks and Steve Jones, this busy session explored why many patients struggle to access pulmonary rehabilitation globally.

My thanks to MEP @JerkovicRomana & the European Respiratory Society for this timely event on "Scaling up EU Prevention policies for Respiratory Health" so important for the #pulmonaryfibrosis & wider #Respiratory Patient community #CurePF

We are pleased to share the positive topline results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough. Join our conference call today, June 2nd, at 8:30 a.m. ET. Read the press release: ow.ly/MCzh50W2spG $TRVI

Dear ILD community, You are cordially invited to this webinar organized by @RespirEffect (REG) tomorrow June 5th at 4 pm BST - UK time (5 pm CEST) 👇 #Screening #EarlyDiagnosis #ILD #PulmonaryFibrosis #PrimaryCare 🫁🌎
REG WEBINARS - REMINDER TO REGISTER 📢 The next REG Webinar is: Screening and early diagnosis of Interstitial Lung Disease: starting the process from Primary Care 🗓️Thursday 5th June 2025 from 5 to 6PM CET 🖥️ Register @ events.teams.microsoft.com/e… #rwe #ild #ipf

Fantastic news for all our patients with IPF who suffer with cough! An overall 43% reduction in cough counts, similar improvement in patient reported cough and benefits seen in 2 weeks. We look forward to the phase 3 study!
We are pleased to share the positive topline results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough. Join our conference call today, June 2nd, at 8:30 a.m. ET. Read the press release: ow.ly/MCzh50W2spG $TRVI

Great to see publication of the first positive phase 3 trial in patients with IPF. This represents an important step forward in the treatment of this terrible disease. #cureipf
Presented at #ATS2025: In the FIBRONEER-IPF phase 3 trial, nerandomilast slowed disease progression in patients with idiopathic pulmonary fibrosis as compared with placebo. Full trial results: nej.md/4mgWcIU @atscommunity